Parkinson’s Disease
Parkinson’s disease is a progressive neurodegenerative condition that primarily affects movement but also produces a wide range of non-motor symptoms. It develops gradually and is most commonly diagnosed in older adults, although early-onset cases do occur. While tremor is often the most recognisable feature, Parkinson’s disease is fundamentally a disorder of impaired neural signalling rather than muscle weakness.
What You Need to Know
Parkinson’s disease is a progressive neurodegenerative disorder caused by loss of dopamine-producing neurons in the substantia nigra, a nucleus within the basal ganglia that helps regulate movement. Dopamine normally acts as a modulator that allows smooth initiation, scaling, and coordination of voluntary movement by balancing excitatory and inhibitory motor pathways. As dopamine levels fall, this balance is disrupted, leading to slowed movement, rigidity, and difficulty initiating motor activity.
At a physiological level, dopamine depletion alters communication within basal ganglia circuits, shifting motor output toward excessive inhibition of movement.
This disruption results in:
Reduced activation of motor pathways responsible for initiating movement
Increased inhibitory signalling that suppresses normal motor output
Impaired automatic motor control, making movements slower and more effortful
Parkinson’s disease also involves abnormal accumulation of intracellular protein aggregates called Lewy bodies, composed largely of misfolded alpha-synuclein. These inclusions interfere with normal cellular processes, including mitochondrial function and protein degradation, contributing to progressive neuronal death. Importantly, neurodegeneration extends beyond motor pathways, affecting cortical and autonomic regions of the nervous system. This broader involvement explains why Parkinson’s disease presents with prominent non-motor features, including cognitive change, mood disturbance, autonomic dysfunction, and sleep disorders, often emerging alongside or even before motor symptoms.
Beyond the Basics
Parkinson’s disease as a multisystem disorder
Parkinson’s disease is now understood as a multisystem neurodegenerative condition rather than a disorder limited to dopaminergic motor pathways. While loss of dopamine-producing neurons in the substantia nigra explains the classic motor features, degeneration also affects other neurotransmitter systems throughout the central and peripheral nervous systems. Cholinergic pathways, which are involved in cognition and attention, serotonergic pathways that influence mood and sleep, and noradrenergic pathways that regulate arousal and autonomic function are commonly affected.
Involvement of these non-dopaminergic systems explains why symptoms such as cognitive impairment, depression, anxiety, autonomic dysfunction, and sleep disturbance are common and may appear years before motor symptoms. This broader pattern of neurodegeneration highlights that Parkinson’s disease affects widespread neural networks, not just those responsible for movement.
Cellular dysfunction and Lewy body pathology
At a cellular level, Parkinson’s disease is characterised by accumulation of abnormal intracellular protein aggregates known as Lewy bodies, which are primarily composed of misfolded alpha-synuclein. These inclusions interfere with essential cellular processes, including mitochondrial function, meaning the cell’s ability to produce energy is impaired. They also disrupt protein clearance pathways, such as the ubiquitin–proteasome system, which normally removes damaged or misfolded proteins.
As these protective systems fail, intracellular transport becomes inefficient and cellular stress increases. Neurons are particularly vulnerable to this disruption because of their high energy demands and long axonal projections. Over time, accumulated cellular dysfunction leads to progressive neuronal injury and death, extending beyond motor circuits and contributing to the wide variability in symptom patterns and disease progression between individuals.
Disease progression and treatment-related complexity
In the early stages of Parkinson’s disease, surviving neurons can partially compensate for dopamine loss by increasing dopamine synthesis and release. This compensatory capacity allows relatively stable motor control and explains why early symptoms may respond well to low-dose therapy. As neurodegeneration progresses, this buffering ability diminishes and motor symptoms become more pronounced.
Long-term dopamine replacement therapy introduces additional complexity. Dopamine receptors are exposed to intermittent, or pulsatile, stimulation rather than the continuous physiological dopamine signalling seen in a healthy brain. Combined with ongoing neuronal loss, this contributes to motor fluctuations and dyskinesias, which are involuntary movements caused by excessive dopaminergic stimulation. These changes reflect a narrowing therapeutic window, where small variations in dopamine levels can shift patients between under-treatment and over-stimulation, making symptom management increasingly challenging in later disease stages.
Clinical Connections
The motor features of Parkinson’s disease, including bradykinesia, rigidity, resting tremor, and postural instability, arise from disrupted basal ganglia signalling due to reduced dopamine availability. Bradykinesia presents as slowed movement, difficulty initiating tasks, reduced arm swing, diminished facial expression, and a short, shuffling gait. Rigidity contributes to stiffness, pain, reduced mobility, and fatigue, while postural instability increases falls risk, particularly during turning or changes in direction as the disease progresses.
Non-motor manifestations carry significant clinical implications and often contribute more to functional decline than motor symptoms alone. Autonomic dysfunction may present as orthostatic hypotension, constipation, urinary urgency, or impaired thermoregulation, increasing vulnerability to falls, dehydration, and skin injury. Cognitive changes and mood disturbance, including depression, anxiety, and executive dysfunction, affect communication, safety awareness, and the ability to manage medications consistently, particularly in later stages.
Key areas requiring close attention in day-to-day care include:
Consistency and timing of dopaminergic medication, as delays can lead to sudden worsening of mobility and rigidity
Swallowing function, with dysphagia increasing aspiration and nutritional risk
Postural blood pressure changes associated with autonomic involvement and falls
Motor and non-motor symptoms often fluctuate across the day in relation to medication cycles and disease stage. Considering these changes together supports safer care, anticipatory planning, and more effective support for individuals living with Parkinson’s disease and those involved in their ongoing care.
Concept Check
Which brain structure is primarily affected in Parkinson’s disease, leading to dopamine depletion?
How does reduced dopamine disrupt normal motor control within the basal ganglia?
Why do non-motor symptoms often appear before classic motor features?
How does the pathophysiology of Parkinson’s disease increase falls risk?
Why is medication timing particularly important in the management of Parkinson’s disease?